amonafide has been researched along with Carcinoma, Hepatocellular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y; Jia, H; Li, L; Li, Y; Ma, J; Ma, R; Ma, Y; Su, S; Wang, C; Wang, J; Xie, S; Yu, L; Yue, K; Zhang, P; Zhang, Z | 1 |
| Li, Q; Li, Z; Wang, CJ; Xie, SQ; Zhang, YH; Zhao, J | 1 |
2 other study(ies) available for amonafide and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
A naphthalimide-polyamine conjugate preferentially accumulates in hepatic carcinoma metastases as a lysosome-targeted antimetastatic agent.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Lysosomes; Molecular Structure; Naphthalimides; Polyamines; Structure-Activity Relationship | 2021 |
BND-12, a novel nonhaematotoxic naphthalimide derivative, inhibits tumour growth and metastasis of hepatocellular carcinoma.
Topics: Adenine; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Humans; Liver Neoplasms; Male; Mice; Mitochondria; Naphthalimides; Neoplasm Metastasis; Organophosphonates; Survival Rate; Toxicity Tests; Xenograft Model Antitumor Assays | 2012 |